Mavacoxib

Mavacoxib
Clinical data
Trade names	Trocoxil
AHFS/Drugs.com	International Drug Names
ATCvet code	QM01AH92 (WHO) ;
Legal status
Legal status	EU: Rx-only;
Identifiers
CAS Number	170569-88-7;
PubChem CID	9843089;
ChemSpider	8018804;
UNII	YFT7X7SR77;
ChEBI	CHEBI:76207;
CompTox Dashboard (EPA)	DTXSID90168880 ;
ECHA InfoCard	100.248.948
Chemical and physical data
Formula	C16H11F4N3O2S
Molar mass	385.34 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=CC(=CC=C1C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F)F;
	InChI InChI=1S/C16H11F4N3O2S/c17-11-3-1-10(2-4-11)14-9-15(16(18,19)20)22-23(14)12-5-7-13(8-6-12)26(21,24)25/h1-9H,(H2,21,24,25); Key:TTZNQDOUNXBMJV-UHFFFAOYSA-N;

Mavacoxib (trade name Trocoxil) is a veterinary drug used to treat pain and inflammation in dogs with degenerative joint disease. It acts as a COX-2 inhibitor.

Mavacoxib, along with several other COX-2 selective inhibitors, including celecoxib, valdecoxib, and parecoxib, were discovered by a team at the Searle division of Monsanto led by John Talley.